NYNeeva Wernsman Young

Neeva Wernsman Young

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Neeva Wernsman Young has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Malaria Treatment Adherence in Rwanda: Implications for Artemisinin Resistance

    by Pierre Gashema, Aileen Jordan, Eric Saramba, Neeva Wernsman Young, Patrick Gad Iradukunda, Corine Karema, Jean Baptiste Mazarati, Jonathan J. Juliano, Jeffrey A. Bailey, Kristin Banek

    : Prompt diagnosis and effective treatment are key malaria interventions that rely on community knowledge and adherence to treatment. With the emergence of artemisinin resistance in Rwanda, ensuring optimal malaria treatment practices within communities is essential. This study examined malaria knowledge, attitudes, and practices among febrile patients at government clinics to identify factors influencing malaria treatment practices. A cross-sectional study was conducted in six health facilities in moderate- to high-malaria-transmission areas of Rwanda. Patients or caregivers of children with fevers were enrolled and interviewed using semistructured questionnaires. From December 2023 to February 2024, 406 participants were enrolled; 71% ( n = 289/406) of participants owned insecticide-treated nets, and 51% ( n = 205/406) received indoor residual spraying. Malaria knowledge was high among respondents, with 81% ( n = 329/406) correctly identifying symptoms, 72% ( n = 291/406) understanding transmission modes, and 74.6% ( n = 303/406) aware of effective control measures. However, of the 44.3% ( n = 180/406) who received malaria treatment in the last 6 months, only 46% ( n = 83/180) completed the appropriate 3-day medication course; 37% ( n = 66/180) stopped within 2 days, and 11% ( n = 19/180) went over 3 days. Furthermore, 27% ( n = 109/406) took antimalarials for fever; the majority (54%; n = 49/109) received medication from drug outlets/pharmacies. Although knowledge and attitudes toward malaria treatment were high, adherence was poor, thereby exacerbating the risk of developing resistance. Effective interventions are urgently needed to improve antimalarial adherence, particularly in sub-Saharan African countries with documented antimalarial resistance.


  • Open Access

    Toward Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and “Why”

    by Jonathan J. Juliano, Cecile P. G. Meier-Scherling, Neeva Wernsman Young, George A. Tollefson, Sean V. Connelly, Jonathan B. Parr, Melissa D. Conrad, Jacob M. Sadler, Christopher M. Hennelly, Ashenafi Assefa, et al.

    : The coronavirus disease 2019 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to address challenges such as artemisinin partial resistance and deletions in the Plasmodium falciparum histidine-rich protein 2 and 3 genes. However, variability in reporting sequencing methods and data reporting currently limits the validation, comparability, and reuse of data. To maximize the impact of MMS, minimal and optimal data that are key for validation and maximizing transparency and findable, accessible, interoperable, and reusable principles are proposed for reporting. Rather than focusing on specific data formats, in the current study, the authors propose what should be reported and why. Progressing to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advancing research and strengthening global public health efforts.


  • Open Access

    Towards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and the “Why”

    by Jonathan Juliano, Cecile Meier-Scherling, Neeva Wernsman Young, George Tollefson, Sean Connelly, Jonathan Parr, Melissa Conrad, Jacob Sadler, Christopher Hennelly, Ashenafi Assefa, et al.

    The COVID-19 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to tackle challenges like artemisinin partial resistance and Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions. However, variability in reporting sequencing methods and data reporting is currently limiting the validation, comparability, and reuse of data. To maximize the impact of MMS, we propose minimal and optimal data for reporting that are key for validation and maximize transparency and FAIR (Findable, Accessible, Interoperable, Reusable) principles. Rather than focusing on specific data formats, here, we propose what should be reported and why. Moving to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advance research and strengthen global public health efforts.